SOURCE: Equity Markets Inc.

October 03, 2011 09:00 ET

Global Situation & Resulting Influences - Research Report on Akorn, Inc. and Par Pharmaceutical Companies, Inc.

MACAU--(Marketwire - Oct 3, 2011) - Today, announced its research report highlighting Akorn, Inc. (NASDAQ: AKRX) and Par Pharmaceutical Companies, Inc. (NYSE: PRX). Full content and research is available at

Continued confidence in long-term U.S. debt is defying S&P's recent downgrade. Treasury yields continue at their lowest levels since January 1, 2011 as the market moved to "safe investments," wary of the storm clouds ahead. Winds can change however, as a last-minute move to save the U.S. from a historic default on its debt obligations. Attentions are now turned to the situation in Europe, with the health of the Euro in the balance; bankers are looking to prevent defaults on Italian and Spanish debt.

As a result of recent credit adjustments, opportunity is being marked for investors to take advantage of equities with high-margin and specialty products. Market-wise investors are carefully watching for value within equities boasting established pipelines and excellent growth prospects. As part of this process, the following companies have been introduced with initial research reports available online.

Equity Markets has reviewed Akorn, Inc. for its current position within the healthcare industry. Akorn, Inc. manufactures and markets a range of diagnostic and therapeutic ophthalmic pharmaceuticals, as well as niche hospital drugs and injectable pharmaceuticals. In addition, the Company has marketed and distributed vaccines purchased from outside sources. The Company operates in three segments: ophthalmic; hospital drugs and injectables, and contract services. The full research report on Akorn, Inc. (NASDAQ: AKRX) is available here:

Equity Markets has reviewed Par Pharmaceutical Companies, Inc. for its development within the healthcare industry. Par Pharmaceutical Companies, Inc. is a holding company that, principally through its wholly owned operating subsidiary, Par Pharmaceutical, Inc., is in the business of developing, licensing, manufacturing, marketing and distributing generic and branded drugs in the United States. The full research report on Par Pharmaceutical Companies, Inc. (NYSE: PRX) is available here:

About Equity Markets
Our mission at Equity Markets is to be the best source of content and research, while educating, enlightening and informing investors. Equity Markets combines street smart analysts and professional market researchers to provide investors with detailed company profiles and market coverage.

Contact Information